September 30, 2022 02:03 PM EDTUpdated 02:48 PM

Industry groups call to block WTO IP waiver expansion to Covid-19 therapeutics

Zachary Brennan

Senior Editor

The WTO’s TRIPS Council in mid-October is expected to debate whether to extend the IP waiver for Covid-19 vaccines to therapeutics and diagnostics too. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Industry groups call to block WTO IP waiver expansion to Covid-19 therapeutics

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Takeda to pay $200M for rights to anemia drug from Keros

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Revolution sells $600M in shares on back of RAS inhibitor portfolio updates

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Gilead makes another ADC move, inking up to $415M pact with Tubulis

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

In­dus­try groups call to block WTO IP waiv­er ex­pan­sion to Covid-19 ther­a­peu­tics

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Industry groups call to block WTO IP waiver expansion to Covid-19 therapeutics

Takeda to pay $200M for rights to anemia drug from Keros

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Revolution sells $600M in shares on back of RAS inhibitor portfolio updates

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Gilead makes another ADC move, inking up to $415M pact with Tubulis

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech